MedTrace Logo

The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

NCT05344027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2023-03-08

No results posted yet for this study

Summary

This work will evaluate the effects of mitotane treatment on serum protein concentrations in patients treated for ACC with mitotane therapy and compare them to patients with an adrenal neoplasm and pregnant cohort. All of the individuals were treated at King's Hospital between April 2019 and June 2020. Proteins which will be evaluated during this study, include CBG and TBG.

Conditions

  • Adrenocortical Carcinoma

Interventions

DRUG

Mitotane

Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2023-01-30
Completion
2023-03-01
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05344027 on ClinicalTrials.gov